Background: Sclerostin is an osteocyte-derived inhibitor of the Wnt/beta-catenin signalling pathway, which acts as a negative regulator of bone formation. Clinical studies have found increased serum sclerostin in patients with type 1 and type 2 diabetes. But, there are none about the relationship between sclerostin and new onset diabetes after transplantation (NODAT). So, the aim of our study is to evaluate sclerostin patients with liver transplantation (LT).
Methods: Cross-sectional study in 85 LT patients. 75 g oral glucose tolerance test was performed (OGTT) and diagnostic ADA criteria were followed. Biochemical data: Plasma glucose (PG), (baseline, 60 and 120 min after OGTT). Serum sclerostin was measured in fasting samples (Enzyme immunoassay).
Results: males, 35 females were included in the study. Mean age was 58.6±12.5 years. 6 patients (7.05%) showed diabetes (NODAT), 31 patients (36.4%) prediabetes and 48 patients (64%) normal glucose tolerance (NGT). Mean sclerostin was: 1.36±0.88 ng/ml in patients with NODAT, 0.81±0.26 ng/ml in patients with prediabetes, 0.78±0.38 ng/ml in the total group and 0.69±0.28 ng/ml in patients with NGT. Significant differences were found in sclerostin levels between NODAT and NGT patients (p<0.001) and NODAT and prediabetes patients (p<0.01). Significant correlations were found between sclerostin and fasting PG (r=0.33;p=0.002); 60-minute PG (r=0.34;p=0.002); 120-minute PG (r=0.43;p<0.001); age (r=0.36;p=0.001). Multiple regression analysis showed that only age and fasting PG remained as independent predictors of sclerostin levels (standardised beta 0.29,p=0.006; 0.24,p<0.05 respectively).
Conclusions: We have found that sclerostin was significantly correlated with plasma glucose and age. Moreover, these results showed that sclerostin levels were significantly higher after LT in patients with NODAT than in patients with prediabetes or NGT. We believe that large-scale studies are needed to investigate the link of higher levels of sclerostin in NODAT patients and increased fracture risk.
Disclosure: The authors declared no competing interests. Fundación Mutua Madrileña granted this project (Number: 2010/016).